Use of Biochemical Markers in Acute Coronary Syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage

AbstractThis paper presents evidence and suggestions from the IFCC Committee on “Standardization of Markers of Cardiac Damage” (C-SMCD) on the use of biochemical markers for the triage diagnosis of acute coronary syndromes. There is general agreement that both ‘early’ and ‘definitive’ biochemical markers of myocardial damage are necessary and that these assays must be available with a turnaround time of 1 h or less. Currently, myoglobin is the marker that most effectively fits the role as an ‘early’ marker, whereas ‘definitive’ markers are cardiac troponins. Since the sensitivity of the initial electrocardiogram is only 50 % for detecting myocardial infarction, the use of biochemical markers may significantly contribute to the early diagnosis and become relevant when the electrocardiogram is not diagnostic. In addition, new sensitive biochemical markers, particularly the cardiac troponins, are presently the best to detect the presence of minor myocardial cell damage. With regard to this, two decision limits are probably needed for the optimal use of troponins: a low abnormal value suggesting the presence of myocardial damage and a higher value suggesting the diagnosis of myocardial infarction according to traditionally used criteria. Properly designed studies should be performed to establish limits for each commercially available troponin assay. Finally, it is recognized that there is no need for the use of any biochemical marker when the clinical diagnosis is unequivocal, other than for diagnosing reinfarction, estimating the infarct size, and monitoring thrombolytic therapy.